Biological specimen banks in neonatal screening

Area of Science:

• Neonatal screening
• Biobanking
• Public health

Background:

• The Danish neonatal screening program analyzes approximately 70,000 dried blood spot samples (DBSS) annually.
• Since 1982, DBSS have been stored at -20°C in a regulated biobank, with parental consent and opt-out options.
• The biobank is governed by specific legislation since 1993, ensuring its unique operational framework.

Purpose of the Study:

• To outline the established procedures and diverse applications of the Danish neonatal screening biobank.
• To highlight the biobank's utility for diagnosis, treatment, quality assurance, and research.
• To demonstrate the value of stored samples for retrospective studies and evaluating new screening methods.

Main Methods:

• Dried blood spot samples (DBSS) collected from newborns are stored after routine analysis.
• Biochemical and molecular genetic assays are employed for diagnosing genetic diseases.
• Immunoassays for specific IgM antibodies and nucleic acid tests are used for infectious disease diagnosis (CMV, toxoplasmosis).

Main Results:

• The biobank has successfully supported the diagnosis of various genetic diseases.
• Congenital cytomegalovirus (CMV) and toxoplasmosis infections have been diagnosed using stored samples.
• Retrospective screening projects using biobank samples have enabled rapid evaluation of novel screening modalities.

Conclusions:

• The neonatal screening biobank provides significant benefits for individual testees and future newborn generations.
• The comprehensive and unbiased nature of the samples makes them invaluable for epidemiological research and advancing screening technologies.
• Long-term storage of neonatal screening samples is crucial for ongoing public health initiatives and medical research.